IMC-M113V
Human Immunodeficiency Virus (HIV)
Phase 1Active
Key Facts
About Immunocore
Immunocore is a UK-based, publicly traded biotech focused on developing transformative T cell receptor-based immunotherapies. Its core achievement is the 2022 launch of KIMMTRAK (tebentafusp), the first-ever approved TCR therapy, for metastatic uveal melanoma. The company is advancing a broad pipeline of bispecific candidates across oncology, virology (HBV, HIV), and autoimmunity using its modular ImmTAX platform, positioning it as a leader in next-generation targeted immunomodulation.
View full company profile